Predictive and Prognostic Value of CYFRA 21-1 for Advanced Non-small Cell Lung Cancer Treated with EGFR-TKIs

被引：29

作者：

Takeuchi, Akira ^{[1
]}

Oguri, Tetsuya ^{[1
]}

Sone, Kazuki ^{[1
]}

Ito, Keima ^{[1
]}

Kitamura, Yuki ^{[1
]}

Inoue, Yoshitsugu ^{[1
]}

Asano, Takamitsu ^{[1
]}

Fukuda, Satoshi ^{[1
]}

Kanemitsu, Yoshihiro ^{[1
]}

Takakuwa, Osamu ^{[2
,3
]}

Ohkubo, Hirotsugu ^{[1
]}

Takemura, Masaya ^{[1
]}

Maeno, Ken ^{[1
]}

Ito, Yutaka ^{[1
]}

Niimi, Akio ^{[1
]}

机构：

[1] Nagoya City Univ, Grad Sch Med Sci, Dept Resp Med Allergy & Clin Immunol, Nagoya, Aichi, Japan

[2] Nagoya City Univ, Grad Sch Med Sci, Dept Educ, Nagoya, Aichi, Japan

[3] Nagoya City Univ, Grad Sch Med Sci, Res Ctr Adv Med, Nagoya, Aichi, Japan

来源：

ANTICANCER RESEARCH | 2017年 / 37卷 / 10期

关键词：

Cytokeratin; 19; fragment; tumor marker; EGFR-TKI; non-small-cell lung cancer; RANDOMIZED PHASE-3 TRIAL; 1ST-LINE TREATMENT; OPEN-LABEL; CHEMOTHERAPY; ERLOTINIB; MUTATION; FRAGMENT; GEFITINIB; EFFICACY; AFATINIB;

D O I：

10.21873/anticanres.12018

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Background: Tyrosine kinase inhibitors (TKIs) directed against epidermal growth factor receptor (EGFR) are important in the treatment of non-small cell lung cancer (NSCLC), especially those harboring EGFR mutations. But little is known regarding the clinical value of serum tumor marker levels measured prior to treatment. Patients and Methods: We retrospectively reviewed 95 patients with advanced NSCLC treated with EGFR-TKIs, and inspected the relationship between serum tumor marker levels and clinical outcome. Results: Forty-three patients with an elevated serum level of cytokeratin 19 fragment (CYFRA 21-1) had shorter progression-free (PFS) and overall (OS) survival than 52 patients with normal serum CYFRA 21-1 levels (99 vs. 123.5 days p=0.011; and 385 vs. 607 days, respectively, p=0.001). Regardless of EGFR mutation status, patients had shorter progression-free survival when serum CYFRA 21-1 was elevated. Conclusion: Serum CYFRA 21-1 level may be a predictive factor for patients with NSCLC treated with EGFR-TKIs, regardless of EGFR mutation status.

引用

页码：5771 / 5776

页数：6

共 17 条

[11]

CYFRA 21-1 as a Predictive Marker for Non-small Cell Lung Cancer Treated with Pemetrexed-based Chemotherapy [J].

Sone, Kazuki ;

Oguri, Tetsuya ;

Nakao, Makoto ;

Kagawa, Yusuke ;

Kurowaka, Ryota ;

Furuta, Hiromi ;

Fukuda, Satoshi ;

Uemura, Takehiro ;

Takakuwa, Osamu ;

Kanemitsu, Yoshihiro ;

Ohkubo, Hirotsugu ;

Takemura, Masaya ;

Maeno, Ken ;

Ito, Yutaka ;

Sato, Hidefumi ;

Muramatsu, Hideki ;

Niimi, Akio .

ANTICANCER RESEARCH, 2017, 37 (02) :935-939

[12]

CLINICAL USEFULNESS OF CYFRA ASSAY IN DIAGNOSING LUNG-CANCER - MEASUREMENT OF SERUM CYTOKERATIN FRAGMENT [J].

SUGAMA, Y ;

KITAMURA, S ;

KAWAI, T ;

OHKUBO, A ;

HASEGAWA, S ;

KURIYAMA, T ;

KATO, H ;

FUKUOKA, M ;

OHKAWA, J .

JAPANESE JOURNAL OF CANCER RESEARCH, 1994, 85 (11) :1178-1184

[13]

Cytokeratin 19 Fragment Predicts the Efficacy of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor in Non-Small-Cell Lung Cancer Harboring EGFR Mutation [J].

Tanaka, Kosuke ;

Hata, Akito ;

Kaji, Reiko ;

Fujita, Shiro ;

Otoshi, Takehiro ;

Fujimoto, Daichi ;

Kawamura, Takahisa ;

Tamai, Koji ;

Takeshita, Jumpei ;

Matsumoto, Takeshi ;

Monden, Kazuya ;

Nagata, Kazuma ;

Otsuka, Kyoko ;

Nakagawa, Atsushi ;

Tachikawa, Ryo ;

Otsuka, Kojiro ;

Tomii, Keisuke ;

Katakami, Nobuyuki .

JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (07) :892-898

[14]

Pathologic Diagnosis of Advanced Lung Cancer Based on Small Biopsies and Cytology A Paradigm Shift [J].

Travis, William D. ;

Rekhtman, Natasha ;

Riley, Gregory J. ;

Geisinger, Kim R. ;

Asamura, Hisao ;

Brambilla, Elisabeth ;

Garg, Kavita ;

Hirsch, Fred R. ;

Noguchi, Masayuki ;

Powell, Charles A. ;

Rusch, Valerie W. ;

Scagliotti, Giorgio ;

Yatabe, Yasushi .

JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (04) :411-414

[15]

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial [J].

Wu, Yi-Long ;

Zhou, Caicun ;

Hu, Cheng-Ping ;

Feng, Jifeng ;

Lu, Shun ;

Huang, Yunchao ;

Li, Wei ;

Hou, Mei ;

Shi, Jian Hua ;

Lee, Kye Young ;

Xu, Chong-Rui ;

Massey, Dan ;

Kim, Miyoung ;

Shi, Yang ;

Geater, Sarayut L. .

LANCET ONCOLOGY, 2014, 15 (02) :213-222

[16]

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials [J].

Yang, James Chih-Hsin ;

Wu, Yi-Long ;

Schuler, Martin ;

Sebastian, Martin ;

Popat, Sanjay ;

Yamamoto, Nobuyuki ;

Zhou, Caicun ;

Hu, Cheng-Ping ;

O'Byrne, Kenneth ;

Feng, Jifeng ;

Lu, Shun ;

Huang, Yunchao ;

Geater, Sarayut L. ;

Lee, Kye Young ;

Tsai, Chun-Ming ;

Gorbunova, Vera ;

Hirsh, Vera ;

Bennouna, Jaafar ;

Orlov, Sergey ;

Mok, Tony ;

Boyer, Michael ;

Su, Wu-Chou ;

Lee, Ki Hyeong ;

Kato, Terufumi ;

Massey, Dan ;

Shahidi, Mehdi ;

Zazulina, Victoria ;

Sequist, Lecia V. .

LANCET ONCOLOGY, 2015, 16 (02) :141-151

[17]

Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802) [J].

Zhou, C. ;

Wu, Y. L. ;

Chen, G. ;

Feng, J. ;

Liu, X. -Q. ;

Wang, C. ;

Zhang, S. ;

Wang, J. ;

Zhou, S. ;

Ren, S. ;

Lu, S. ;

Zhang, L. ;

Hu, C. ;

Luo, Y. ;

Chen, L. ;

Ye, M. ;

Huang, J. ;

Zhi, X. ;

Zhang, Y. ;

Xiu, Q. ;

Ma, J. ;

Zhang, L. ;

You, C. .

ANNALS OF ONCOLOGY, 2015, 26 (09) :1877-1883

← 1 2 →